ARDX — Recent News Coverage
All news mentioning ARDX in ESEN's AI-graded feed
News stories with ARDX as an affected ticker. Each article is graded by ESEN AI for impact level and direction (up/down/flat) on ARDX. See /coverage/ARDX for the 30-day aggregate.
SEEKINGALPHA.COM
·
2026-08-12
NEUTRAL
NEUTRAL
CORR0.15
Ardelyx Q2: Strong Demand, But Payer Friction Clouds The Story (NASDAQ:ARDX)
$ARDX
◈ ESEN AI
Ardelyx (ARDX) demonstrated operational momentum in Q2 with 31% year-over-year revenue growth, signaling underlying demand for its therapeutic offerings. However, the earnings report reveals a structural headwind: payer…
SEEKINGALPHA.COM
·
2026-08-07
NEUTRAL
BEARISH
CORR0.15
Ardelyx signals lower 2026 IBSRELA guidance to $350M-$370M while revising 2026 opex to below $500M (NASDAQ:ARDX)
$ARDX
◈ ESEN AI
Ardelyx (ARDX) reported record Q2 2026 revenue of $118M but simultaneously issued a significant guidance reduction for IBSRELA sales, now forecasting $350M–$370M for the full year versus prior expectations. This mixed s…
SEEKINGALPHA.COM
·
2026-08-07
LOW
NEUTRAL
CORR0.35
Ardelyx, Inc. (ARDX) Q2 2026 Earnings Call Transcript
$ARDX
◈ ESEN AI
Ardelyx (ARDX) released Q2 2026 earnings results via earnings call transcript, providing routine disclosure of financial and operational performance for the second quarter. The event represents standard periodic reporti…
SEEKINGALPHA.COM
·
2026-07-02
LOW
BEARISH
CORR0.15
Ardelyx Stock: The Market Is Right To Discount This Revenue Growth (NASDAQ:ARDX)
$ARDX
◈ ESEN AI
Ardelyx (ARDX) faces structural headwinds that justify current market valuation discounts. The company's flagship product Xphozah encountered a significant setback with a failed Medicare reimbursement appeal, a critical…
FINANCE.YAHOO.COM
·
2026-06-23
NEUTRAL
BULLISH
CORR0.35
What’s Fueling Optimism Around Ardelyx, Inc. (ARDX)’s Sales and Pipeline?
$ARDX
◈ ESEN AI
Ardelyx (ARDX) received a new Buy rating and $16 price target from Ladenburg Thal on June 16, reflecting renewed institutional confidence in the biotech company's commercial execution. This catalyst represents a formal …
ECONOMICTIMES.INDIATIMES.COM
·
2026-06-17
NEUTRAL
BULLISH
CORR0.55
Zydus Lifesciences shares in focus as firm acquires US-based Assertio Holdings for $166 million
$ZYDUS
$ARDX
◈ ESEN AI
Zydus Lifesciences has completed its $166.4 million acquisition of Assertio Holdings, a US-based pharmaceutical firm, through a cash tender offer. This transaction positions Zydus to absorb Assertio as a wholly-owned su…
EXPLORE OTHER FILTERS